coiled-coil and C2 domain containing 2BGenealiases: C10orf130 · C10orf131
Q-omics provides the consensus-scored CC2D2B profile across patient tissues and cancer cell-line models. CC2D2B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CC2D2B is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, CC2D2B RNA expression shows 18,745 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, LUSC, and UVM as cancer lineages where CC2D2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CC2D2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CC2D2B survival associations across molecular data types. CC2D2B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CC2D2B RNA expression–survival associations across cancer types. High CC2D2B expression shows unfavorable associations in ACC and LUSC, but favorable associations in LUAD, SKCM, THCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CC2D2B RNA expression.
This table summarizes CC2D2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CC2D2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CC2D2B shows lower tumor expression in LUSC, KICH, UCEC and BLCA and higher tumor expression in THCA and KIRC. The LUSC box plot shows higher CC2D2B RNA expression in normal versus tumor tissue (log2 FC = −0.227, t-test p < 0.001).
This table shows molecular features associated with CC2D2B in patient tissues and cancer cell lines. In patient samples, CC2D2B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CC2D2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
